Announcements Trials
Browse Landscape

Phase

Phase 2 31Phase 1/2 11Phase 1 11Phase NA 8Phase 3 3Phase 2/3 2Phase EARLY_PHASE1 1

Status

Not yet recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Neoplasms 36Carcinoma, Non-Small-Cell Lung 29Prostatic Neoplasms 20Neoplasm Metastasis 19Breast Neoplasms 19Colorectal Neoplasms 17Squamous Cell Carcinoma of Head and Neck 14Leukemia, Myeloid, Acute 14Stomach Neoplasms 12Ovarian Neoplasms 12Melanoma 12Lung Neoplasms 12Carcinoma, Hepatocellular 12Recurrence 11Hematologic Neoplasms 10Endometrial Neoplasms 10Rectal Neoplasms 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Pancreatic Neoplasms 9Lymphoma 9Head and Neck Neoplasms 9Myasthenia Gravis 8Leukemia 8Urinary Bladder Neoplasms 7Neoplasms by Site 7Neoplasms by Histologic Type 7Lymphoma, Large B-Cell, Diffuse 7Glioblastoma 7Fatigue 6Colonic Neoplasms 6

Interventions

venetoclax 1Sorafenib 1Cytarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Neoplasm, Residual × 1 year × Clear all
NCT07537257 2026-04-17

VEN+IDAC vs IDAC in AML

Guangdong Second Provincial General Hospital

Phase 2/3 Enrolling by invitation
232 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT07264010 2025-12-04

Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study

Nanfang Hospital, Southern Medical University

Phase 2/3 Not yet recruiting
87 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡